The Global Healthcare Study on Hidradenitis Suppurativa (GHSHS) is an international, multicenter observational study hosted by the University of Zurich (UZH) investigating healthcare access, treatment patterns, disease severity, and quality of life in patients with psoriasis. The study collects standardized clinical data from routine medical records to identify disparities in healthcare delivery and outcomes across different healthcare systems.
The study employs a combined retrospective and prospective design, collecting data from routine clinical care and medical records spanning from January 2020 through the study conclusion.
Study Type
OBSERVATIONAL
Enrollment
9,600
University of Zurich
Zurich, Switzerland
RECRUITINGInternational Hidradenitis Suppurativa Severity Score System (IHS4)
Clinician-assessed measure of hidradenitis suppurativa severity based on the number of inflammatory nodules, abscesses, and draining tunnels; higher scores indicate more severe disease.
Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.
Hurley Staging System
Clinician-assessed classification of hidradenitis suppurativa severity categorized as Stage I, Stage II, or Stage III.
Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.
Sartorius Hidradenitis Suppurativa Severity Score (HSS)
Clinician-assessed measure of hidradenitis suppurativa severity incorporating lesion counts and anatomical involvement; higher scores indicate more severe disease.
Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.
Physician Global Assessment (PGA)
Clinician-assessed global measure of hidradenitis suppurativa severity on a scale from 0 to 4, with higher scores indicating more severe disease.
Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.
Dermatology Life Quality Index (DLQI)
Patient-reported measure of dermatology-specific quality of life; total score ranges from 0 to 30, with higher scores indicating greater impairment.
Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.
Patient-reported Numerical Rating Scale (NRS) for severity of hidradenitis suppurativa
Patient-reported assessment of overall hidradenitis suppurativa severity on a numerical rating scale from 0 (no disease) to 10 (most severe disease imaginable).
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.
Patient-reported Numerical Rating Scale (NRS) for pain related to hidradenitis suppurativa
Patient-reported assessment of hidradenitis suppurativa-related pain on a numerical rating scale from 0 (no pain) to 10 (worst imaginable pain).
Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.